๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Tetrandrine ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats

โœ Scribed by Wang Hai; Chen Xiaoping

Book ID
105635750
Publisher
Springer-Verlag
Year
2004
Tongue
Chinese
Weight
460 KB
Volume
24
Category
Article
ISSN
0510-9752

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Comparison of vascular nitric oxide prod
Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats
โœ M Niederberger; P Gines; P Martin; P Tsai; K Morris; I McMurtry; R W Schrier ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 244 KB ๐Ÿ‘ 1 views

sults suggest that vascular NO production is higher in Nitric oxide (NO) is postulated to play a role in the cirrhotic rats than in PVL rats. This increased producpathogenesis of arterial vasodilation in chronic portal tion may contribute to the more marked abnormalities hypertension. This present s

Thalidomide inhibits tumor necrosis fact
Thalidomide inhibits tumor necrosis factor ฮฑ, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats
โœ J C Lopez-Talavera; G Cadelina; J Olchowski; W Merrill; R J Groszmann ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 281 KB

Portal hypertension accompanied by anatomic or served in portal hypertension with liver failure or extenfunctional portal-systemic shunting very often is assosive portal-systemic shunting. Tumor necrosis factor a ciated with a hyperdynamic circulatory state. The so-(TNF) causes marked hypotension in

Atorvastatin lowers portal pressure in c
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase
โœ Jonel Trebicka; Martin Hennenberg; Wim Laleman; Nataliya Shelest; Erwin Biecker; ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 685 KB

In cirrhosis, increased RhoA/Rho-kinase signaling and decreased nitric oxide (NO) availability contribute to increased intrahepatic resistance and portal hypertension. Hepatic stellate cells (HSCs) regulate intrahepatic resistance. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins)